How Has HCV Treatment Transformed the Potential for HCV Elimination?

In this downloadable slideset, Jordan J. Feld, MD, MPH, and Natasha Martin, DPhil, review how dramatic changes in the HCV treatment landscape have enabled high cure rates to be safely achieved across a wide range of patient populations, including those previously excluded from HCV therapy because of previous or ongoing injection drug use.
Format: Microsoft PowerPoint (.ppt)
File Size: 420 KB
Released: October 18, 2017

Acknowledgements

Educational grant provided by:
Gilead Sciences

Related Content

CCO downloadable slides from Dr. Tatyana Kushner providing insights on updated guidance for HCV screening and management in women of childbearing age

Tatyana Kushner, MD, MSCE Released: January 8, 2021

CCO module by Dr. Mark Sulkowski on optimal HCV management in PWID, children, liver transplant recipients and patients with renal disease or HIV

Stefan Zeuzem, MD
Program Director
Mark S. Sulkowski, MD
Released: December 28, 2020

CCO commentary from Catherine Chappell, MD, MSc, on the challenges of HCV management in women of childbearing age, including during pregnancy.

person default Catherine Chappell, MD, MSc Released: December 22, 2020

CCO commentary from Tatyana Kushner, MD, MSCE, on the important role of universal HCV testing for pregnant women

Tatyana Kushner, MD, MSCE Released: December 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue